Allt inom Other Corporate Information
Continued Good Tolerability of NEX-22 at 30 mg Dose of Liraglutide in the NEX-22 Study
Nanexa AB announces that initial observations in the phase I study show that the 30 mg dose of NEX-22, a depot formulation of liraglutide, has been well tolerated by patients with type 2 diabetes who have not previously received GLP-1 treatment.
Nanexa doses the last patients with 30 mg liraglutide in the NEX-22-01 study
Nanexa announces that all patients have now been included in the fourth and final dose cohort in the Phase I study of NEX-22, a one-month formulation of liraglutide.